drugset / Trial / NCT05394012
A Phase 1a Trial to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 mRNA Chimera Vaccine Against COVID-19
Phase 1
Unknown
120 enrolled
Walvax Biotechnology Co., Ltd.
Shanghai RNACure Biopharma Co., Ltd. · collab
RandomizedParallel-groupDouble-blindPrevention
Summary
This is a phase Ⅰa, randomized, double-blind, positive control trial in healthy adults, intended to evaluate the safety and immunogenicity profile of RQ3013. The study vaccine is administered IM at upper arm deltoid as a two-dose primary series on day 0, 28.
Timeline
- Start
- 2022-12
- Primary completion
- 2023-02
- Completion
- 2023-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | BNT162b2 | Messenger RNA (mRNA) | 30 ug | — |
| Subject | RQ3013 | Messenger RNA (mRNA) | 30 ug | Intramuscular |
| Subject | RQ3013 | Messenger RNA (mRNA) | 60 ug | Intramuscular |